Abstract
Once the genetic defect of cystic fibrosis (CF), the most common autosomal recessive disease, was discovered, there was hope for quick positive results with gene-therapy. These did not came true, however. Recent CF mice studies by Freedman et al. demonstrated a disease reversal by high doses of docosahexaenoic acid (DHA). Although it is known for long that the same essential fatty acid imbalance with low levels of DHA is present in CF patients and that DHA has antiinflammatory actions, caution is urged to prevent false expectations when we extrapolate mice model results. This review explores the present scientific data on DHA supplementation in CF.
Keywords: Polyunsaturated Fatty Acids, CF transmembrane conductance regulator (CFTR), Phospholipid, Eicosapentaenoic acid, inflammation
Current Pediatric Reviews
Title: Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis
Volume: 2 Issue: 2
Author(s): Stephanie v. Biervliet, Jean-Pierre v. Biervliet, Eddy Robberecht and Armand Christophe
Affiliation:
Keywords: Polyunsaturated Fatty Acids, CF transmembrane conductance regulator (CFTR), Phospholipid, Eicosapentaenoic acid, inflammation
Abstract: Once the genetic defect of cystic fibrosis (CF), the most common autosomal recessive disease, was discovered, there was hope for quick positive results with gene-therapy. These did not came true, however. Recent CF mice studies by Freedman et al. demonstrated a disease reversal by high doses of docosahexaenoic acid (DHA). Although it is known for long that the same essential fatty acid imbalance with low levels of DHA is present in CF patients and that DHA has antiinflammatory actions, caution is urged to prevent false expectations when we extrapolate mice model results. This review explores the present scientific data on DHA supplementation in CF.
Export Options
About this article
Cite this article as:
Biervliet v. Stephanie, Biervliet v. Jean-Pierre, Robberecht Eddy and Christophe Armand, Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis, Current Pediatric Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339606776894658
DOI https://dx.doi.org/10.2174/157339606776894658 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews Advances in Inhibitors of FXa
Current Drug Targets Targeted Therapies in Hepatocellular Carcinoma
Current Medicinal Chemistry Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis
Recent Patents on Biotechnology Novel Approaches to the Treatment of Obesity and Type 2 Diabetes Mellitus: Bioactive Leptin-Related Synthetic Peptide Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) N-Acetyl Cysteine in Rodenticide Poisoning: A Systematic Review and Meta-Analysis
Current Reviews in Clinical and Experimental Pharmacology Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Matrix Metalloproteinases in Venous Tissue Remodeling and Varicose Vein Formation
Current Vascular Pharmacology Advances in Antithrombotic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug-Induced Hypokalaemia
Current Drug Safety Adjuvant Therapies of COVID-19 - A Literature Review
Coronaviruses Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy
Current Pharmaceutical Design Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies
Cardiovascular & Hematological Agents in Medicinal Chemistry Thrombotic Complications of Neonates and Children with Congenital Nephrotic Syndrome
Current Pediatric Reviews Biologically Active Dietary Peptides
Mini-Reviews in Medicinal Chemistry The Progress on the In Vivo-In Vitro Correlation (IVIVC) for Immediate Release Dosage Form as an Alternative to Bioavailability Studies
Current Pharmaceutical Analysis